{"id":1006876,"date":"2026-09-29T18:31:59","date_gmt":"2026-09-29T22:31:59","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/dbv-technologies-announces-submission-of-biologics-license-application-to-u-s-fda-for-the-viaskin-peanut-patch-in-children-aged-4-7-years\/"},"modified":"2026-09-29T18:31:59","modified_gmt":"2026-09-29T22:31:59","slug":"dbv-technologies-announces-submission-of-biologics-license-application-to-u-s-fda-for-the-viaskin-peanut-patch-in-children-aged-4-7-years","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/dbv-technologies-announces-submission-of-biologics-license-application-to-u-s-fda-for-the-viaskin-peanut-patch-in-children-aged-4-7-years\/","title":{"rendered":"DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the\u00a0VIASKIN\u00ae Peanut Patch in Children Aged 4-7 Years"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"right\"> Ch\u00e2tillon, France, September 29, 2026<\/p>\n<p align=\"justify\">\n        <b>DBV Technologies Announces Submission of Biologics License Ap<\/b><br \/>\n        <b>p<\/b><br \/>\n        <b>lication to U.S. FDA for the\u00a0VIASKIN<\/b><br \/>\n        <sup><br \/>\n          <b>\u00ae<\/b><br \/>\n        <\/sup><br \/>\n        <b> Peanut Patch in Children Aged 4-7 Years <\/b>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">The\u00a0BLA\u00a0is supported\u00a0by\u00a0the\u00a0results from the successful Phase 3\u00a0VITESSE trial\u00a0\u2013 the largest\u00a0immunotherapy clinical trial to date for this population.\u00a0<\/li>\n<li style=\"margin-bottom:12pt;text-align:justify\">DBV has requested Priority Review of the BLA.<\/li>\n<\/ul>\n<p align=\"justify\">DBV Technologies (Euronext: DBV \u2013 ISIN: FR0010417345 \u2013 Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company, today announced that the Company has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the VIASKIN<i>\u00ae<\/i> Peanut Patch in children with peanut allergy aged 4 through 7 years. <\/p>\n<p align=\"justify\">DBV has requested Priority Review of the BLA. The FDA previously granted Breakthrough Therapy Designation to the VIASKIN\u00ae Peanut Patch.<\/p>\n<p align=\"justify\">\n        <i>\u201cThe submission of our BLA brings VIASKIN\u00ae Peanut Patch, a non-invasive, practical treatment option, one step closer to being available for children ages 4 through 7 living with peanut allergy, and marks a significant milestone in DBV\u2019s transformation into a commercial organization,\u201d <\/i><br \/>\n        <b>said Daniel Tass\u00e9, Chief Executive Officer of DBV Technologies.<\/b><br \/>\n        <i> \u201cThis BLA reflects years of rigorous clinical development, meaningful contributions from the entire food allergy community, and ongoing collaboration with the FDA. We are grateful for the Agency\u2019s constructive engagement over the last few months and look forward to working closely with them during the review process.\u201d<\/i>\n      <\/p>\n<p align=\"justify\">The VIASKIN\u00ae Patch uses epicutaneous immunotherapy (EPIT), an innovative, non-oral, non-injection approach to food allergy treatment that delivers small amounts of an allergen protein through the skin. By using the immune properties of the skin, the VIASKIN\u00ae Peanut Patch is designed to progressively desensitize children to peanut allergy. <\/p>\n<p align=\"justify\">The BLA is supported by the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8jMInYRsfvBHrZlnj20owzZe_TfyMNjSzuGpWu50LRXM5vDHb1mTrZaIaDyopfryJdoZSnW3sV0pEEoOvFFw6Qws3bd2yl4_IpDeC0La_gU03KnAH9S0YapQ0VoIL9UI3rz0kg6yrrnmAjZaos2slqbON0JfpeszL8N4IwDApi3gnDEV9yrMrtNVikQ2OONUaw2cenHMZAx-p2STIkesQbG3bmPakIcCkPE0dHe4Ti7UAVsLnJItAidPWIfef1LfR08XfWWFa5qDPIsMO6GaU9fOC0T-QsrQQ8nRIzVl05giVA216kx0emiyVs_q0ggP2mHd4FhbVpgGHG9vDKtlK9j4HeE2PP-nSR7iS8oni6xGeLfR9VSNixa8QHkBDCo5EExdvidVJTO69ZyhUV4SDH8UKGGvllrLqmhye5u_Xqz8kJkyiptOVwVoewKvoGpdzRZy7b5KeL0KoZ6nBeL-wytR4z7uTHvCOi7girpUpN88UmmA2z-BWaBCG2RwAZ31qFkaTp4c34sfQWpklmiZ0bZk73ew2HxRFQ_g8muxoNJfGZIlpCfxQO8Idvw6pZVdJrSZ2R56G4xWI_NJxtViSKO1lFqqfOr4no2aBM1qp1VO-VwHwp_CUErEKUkUKzdObAaWgAtjUDKWmfhQ1IdMziMnbzwRDWT1d_dBcteADwI=\" rel=\"nofollow\" target=\"_blank\">positive results from the VITESSE Phase 3 clinical trial<\/a> of the VIASKIN\u00ae Peanut Patch in 654 children ages 4 through 7 years with peanut allergy. VITESSE is the largest immunotherapy clinical trial to date for this population.<\/p>\n<p align=\"left\">\n        <b>About the VITESSE Study<\/b><br \/>\n        <br \/>VITESSE (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0oapSxDhop6KXvKPyGN6IJY3VOTe6L4j5aBeW41ZhIYlGxsm201Z2iwjkF8VAIvNVqnDOqHMsaCPqIYk78ETTtgKUXgqaEze4LFlX2AeQUfN11h7T7W6bt6HZgqtBFI6-b5U-W8Sdddlm8n1-GG38TAbwqIcbAMuqbcdUnjaSiyEnfEIexIAQvwho54SQe4TOLSXm_qirRzQJwtpNq-w0Qw5Fk78jf2yFUJXYNqmfPFYnl0QhZPqbeJk1xUr3FXZgM30TTsEIOh_cPjl8xCqPgOXRLD7XVU6DuMPj4jUIRUUdbG0eU0SkIGhgf4uFlEyet3ah4KgPPWFUvx6dBpG8nHKNDkk6C_a9eQgTFD0AoJGZ6G8M2ryufitSZi9xumt2PsDjZDU8J0fplGpqKw0eam7c99RjT90Hrts7c7EwJv3vlU5dWcfTAWNuXlj2OCSIg8EUazho_KTcId7jh1igxrlXewAqI-QpG59Jn_GRXM57saVFoA3ZMOoJ3TsSfzYdSASyNgN5YBaqzlnNImI4S3K-LShv669fO7JbifbrrPDg2WVWumMDrtWdSzRptHT-1vKpuNkq0VjjSVk71bbZ51b5kloXuELjldBPYS-BmBkbCrbaDqnEsrsTG18m6_XOUlCm945-aJyGI4c8kfFHbKiMium9TLIOWpT5MUw3Ek9FhxJAqW84LUEv8WLNNhck8rJ0786quWpN-EYZiJMzlTbTAMq9AFoCGQlUuPTmzEvcyZNT2VLVPXktfUJ6sft\" rel=\"nofollow\" target=\"_blank\">NCT05741476<\/a>) is a global Phase 3, randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of the VIASKIN\u00ae Peanut patch (250 \u00b5g) in children ages 4-7 years with peanut allergy. The study enrolled 654\u00a0children\u00a0randomized 2:1 to receive either VIASKIN\u00ae Peanut Patch or placebo. Conducted at 86 sites across the United States, Canada, United Kingdom, Europe, and Australia, VITESSE represents the largest immunotherapy clinical trial for this patient population. The primary endpoint is the difference between the percentage of treatment responders in the active versus placebo group after 12 months of treatment. Following the 12-month double-blind period,\u00a0children\u00a0were given the option to\u00a0continue into an open-label extension where all participants receive VIASKIN\u00ae Peanut Patch for up to a total of three years on treatment.<\/p>\n<p align=\"justify\">\n        <b>About DBV Technologies<\/b><br \/>\n        <br \/>DBV Technologies is a late-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV Technologies is currently focused on investigating the use of its proprietary VIASKIN\u00ae Patch technology to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT), the VIASKIN\u00ae Peanut Patch is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual\u2019s underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin\u2019s immune tolerizing properties. DBV Technologies is committed to transforming the care of people with food allergies. The Company\u2019s food allergy programs include ongoing clinical trials of VIASKIN\u00ae Peanut Patch in toddlers (1 through 3 years of age) and children (4 through 7 years of age) with peanut allergy.<\/p>\n<p align=\"justify\">DBV Technologies is headquartered in Ch\u00e2tillon, France, with North American operations in Warren, NJ. The Company\u2019s ordinary shares are traded on segment B of Euronext Paris (DBV, ISIN code: FR0010417345) and the Company\u2019s ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (DBVT \u2013 CUSIP: 23306J309).<\/p>\n<p align=\"justify\">For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=AYF0YgRFDuTvVhvDo_T3OrylUeeLHWgdz12JzuYKXorocRXQ66b4hEnoRB-c83JA9bzmOMIQvsIxnqM9makFtmnn1sFkyy_6NHMSgf8lxJpOGwEAuWBi_W2-ANvNn7NdkJQWnezLF-ip9Pyzt9e3K13gcDVMxy_11qHMMJ28nZhiAnay7oeIqYq3iJhxpJAUJxb3D2KFVXbxNpkJUCryjgTZ_ryK2bxNkMpHGisPgJuCFOrhdbccg900-X3GCgVcoUHETwGgEtFqOxDDyteUjpwihUIy9narKfokBnHZYiS2MTorVqigDnjwZoR_78Rw9agciQ9emtE0wWW6rviodL7s5xqyKnHWijm4X7Naa4M6BigonNClKno04P7I_twf1i2W_8PsvOdRwUo1OdC7fvrB07Rw61njHhpo7A-jhUM=\" rel=\"nofollow\" target=\"_blank\">www.dbv-technologies.com<\/a> and engage with us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8p235Jz-qhwoWDwwYI5jXYvZvVD_ptw7iQnlpEUc7nWvRO8n7QiskyCyVcV3LWLTEIzFkOQEn9neD1Tfp8u8IldduwDzqS3WQoSOwsLgC7r6P12M-BuE--HvUvXaLAK38b5dUf6YGdydqyby_a4ZHbXLN8JSzcYJnHT78h5d3rjRRCTkxBAHz5fcKBPRTAWKfNeynQikyafAOSHgUuCjGARyRng3Izg5N99dlrz0hyLp9pgnxJ1l7DEZhZpjg9XdGNiIUWgh2SwqgDUOaIJrZGxT4TIECifDt0VAHfl5PAAQcsTvjefp-Of9S_mghHEXNyvXZA0aDtrqHbeFW1beHve8Vc7GnEgQ-vqFSrOIQGBmSo8celM_V-pKihFM8oXWSpJddfsDSLofIEU5MAYIgJrUceq2-OXqNU_O5Cj3UwA=\" rel=\"nofollow\" target=\"_blank\">X (formerly Twitter)<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=vRZg1pRc4LqZgoGdm_RSZYvFwBQiF-cEVf76zojKSVGrqRqfkhxtZTSiJoHyvLs0bOeNwZIi2tDIsjHlbJEACV6j6b5GMdQB04e2wN0eDWLsVWHFgb5mO0r_5yxUiQjR5knvcGVd-ZsyaqNgrZbzAcAirYIMqQAHioP0y2jZd1rfNTWPaolsN_rOvYf-G6AEYC587vnqVUS9fyzu0hxAaJxYqDrE5VbhwMr_8EOHb5u6ye-cIqm20YPP7W2b-YbNmHRZIl4Wj4VE-9NJlbiZ2XfgwjjP7xk2Hyw6AExG_zlgf99EsJsuDCa9b1fbnisyATlW67XnIByOi_YVMSzUBU0FAmuHxoqH4fc9NLpUX5xOV2d33qdyXg1aCYb4scyMh-KGIJkYH08ovk6FAAP-7DcbI0a9JYip7N4hV9ZXSzo=\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>. <\/p>\n<p align=\"justify\">\n        <b>Forward Looking Statements<\/b><br \/>\n        <br \/>This press release may contain forward-looking statements and estimates, including statements regarding the therapeutic potential of VIASKIN\u00ae Peanut patch and EPIT, results of DBV\u2019s clinical trials, DBV\u2019s planned regulatory and clinical efforts including timing and results of communications with regulatory agencies, plans, timing and expectations with respect to priority review of the BLA for VIASKIN\u00ae Peanut Patch for children ages 4 through 7, and the ability of any of DBV\u2019s product candidates, if approved, to improve the lives of patients with food allergies. These forward-looking statements and estimates are not promises or guarantees and involve substantial risks and uncertainties. At this stage, DBV\u2019s product candidates have not been authorized for sale in any country. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, and DBV\u2019s ability to successfully execute on its budget discipline measures. A further list and description of risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements in this press release can be found in DBV\u2019s regulatory filings with the French Autorit\u00e9 des March\u00e9s Financiers (\u201cAMF\u201d), DBV\u2019s filings and reports with the U.S. Securities and Exchange Commission (\u201cSEC\u201d), including in DBV\u2019s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 26, 2026, as amended by Amendment No. 1 on Form 10-K\/A filed with the SEC on April 30, 2026, DBV Technologies\u2019 Quarterly Reports on Form 10-Q for the quarters ended March 31, 2026 and June 30, 2026 filed with the SEC on April 30, 2026 and July 16, 2026, respectively, and future filings and reports made with the AMF and SEC by DBV. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date hereof. Other than as required by applicable law, DBV Technologies undertakes no obligation to update or revise the information contained in this Press Release.<\/p>\n<p align=\"justify\">VIASKIN is a registered trademark of DBV Technologies.<\/p>\n<p align=\"justify\">\n        <b>Investor Relations Contact<\/b><br \/>\n        <br \/>Virginie Boucinha<br \/>DBV Technologies<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=V4hMXdsSpdymSUZK36d8jzrGXWXQWQOJzEp_iLPJwZV_Oe51KU6G-A59T7g4U2F-GQn4fxnz-yoXWaPcH1l3l7Krsl9kNu89vWFRAU0uGaHdUdQtlQ81TjJJsvqB8B7e950L4xih0czzHkf2vgpxWZQzOBP5qqarFYkiBGRMT6o=\" rel=\"nofollow\" target=\"_blank\">Virginie.boucinha@dbv-technologies.com<\/a><\/p>\n<p align=\"justify\">\n        <b>Media Contact<\/b><br \/>\n        <br \/>Brett Whelan<br \/>DBV Technologies<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=FrDUd7isGr8YCh78EwjozeAsHkurJ5uFKQ-6uj_ssSgyfJUsPkx0F8nEaVoxz86EW9JHkp67qr7DDZy_LbTHkASOqUjOcQXC51h8KvDsqowULG5buYRCkLYMI91SMxeqVeedYJGkUBQdaUKM1QAlAA==\" rel=\"nofollow\" target=\"_blank\">Brett.whelan@dbv-technologies.com<\/a>\u00a0<\/p>\n<p id=\"gnw_attachments_section-header\">\n        <strong>Attachment<\/strong>\n      <\/p>\n<ul id=\"gnw_attachments_section-items\">\n<li>\n          <a target=\"_blank\" href=\"https:\/\/ml-eu.globenewswire.com\/Resource\/Download\/2aa67f75-b2c4-4ac1-b104-f486de88fb49\">PDF Version<\/a>\n        <\/li>\n<\/ul>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTI3NTMxOSM0MDI1MTk4NjQjMTAxMTE1Mg==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml-eu.globenewswire.com\/media\/Nzg3NDQ3YjctYjEzOS00MDdkLTkyMTktM2IzZWNjOWMwMjI0LTEwMTExNTItMjAyNi0wOS0yOS1lbg==\/tiny\/DBV-Technologies-S-A-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Ch\u00e2tillon, France, September 29, 2026 DBV Technologies Announces Submission of Biologics License Ap p lication to U.S. FDA for the\u00a0VIASKIN \u00ae Peanut Patch in Children Aged 4-7 Years The\u00a0BLA\u00a0is supported\u00a0by\u00a0the\u00a0results from the successful Phase 3\u00a0VITESSE trial\u00a0\u2013 the largest\u00a0immunotherapy clinical trial to date for this population.\u00a0 DBV has requested Priority Review of the BLA. DBV Technologies (Euronext: DBV \u2013 ISIN: FR0010417345 \u2013 Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company, today announced that the Company has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the VIASKIN\u00ae Peanut Patch in children with peanut allergy aged 4 through 7 years. DBV has requested Priority Review of the BLA. The FDA previously granted Breakthrough Therapy Designation to &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/dbv-technologies-announces-submission-of-biologics-license-application-to-u-s-fda-for-the-viaskin-peanut-patch-in-children-aged-4-7-years\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the\u00a0VIASKIN\u00ae Peanut Patch in Children Aged 4-7 Years&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1006876","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the\u00a0VIASKIN\u00ae Peanut Patch in Children Aged 4-7 Years - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/dbv-technologies-announces-submission-of-biologics-license-application-to-u-s-fda-for-the-viaskin-peanut-patch-in-children-aged-4-7-years\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the\u00a0VIASKIN\u00ae Peanut Patch in Children Aged 4-7 Years - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Ch\u00e2tillon, France, September 29, 2026 DBV Technologies Announces Submission of Biologics License Ap p lication to U.S. FDA for the\u00a0VIASKIN \u00ae Peanut Patch in Children Aged 4-7 Years The\u00a0BLA\u00a0is supported\u00a0by\u00a0the\u00a0results from the successful Phase 3\u00a0VITESSE trial\u00a0\u2013 the largest\u00a0immunotherapy clinical trial to date for this population.\u00a0 DBV has requested Priority Review of the BLA. DBV Technologies (Euronext: DBV \u2013 ISIN: FR0010417345 \u2013 Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company, today announced that the Company has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the VIASKIN\u00ae Peanut Patch in children with peanut allergy aged 4 through 7 years. DBV has requested Priority Review of the BLA. The FDA previously granted Breakthrough Therapy Designation to &hellip; Continue reading &quot;DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the\u00a0VIASKIN\u00ae Peanut Patch in Children Aged 4-7 Years&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/dbv-technologies-announces-submission-of-biologics-license-application-to-u-s-fda-for-the-viaskin-peanut-patch-in-children-aged-4-7-years\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-29T22:31:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTI3NTMxOSM0MDI1MTk4NjQjMTAxMTE1Mg==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dbv-technologies-announces-submission-of-biologics-license-application-to-u-s-fda-for-the-viaskin-peanut-patch-in-children-aged-4-7-years\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dbv-technologies-announces-submission-of-biologics-license-application-to-u-s-fda-for-the-viaskin-peanut-patch-in-children-aged-4-7-years\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the\u00a0VIASKIN\u00ae Peanut Patch in Children Aged 4-7 Years\",\"datePublished\":\"2026-09-29T22:31:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dbv-technologies-announces-submission-of-biologics-license-application-to-u-s-fda-for-the-viaskin-peanut-patch-in-children-aged-4-7-years\\\/\"},\"wordCount\":1083,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dbv-technologies-announces-submission-of-biologics-license-application-to-u-s-fda-for-the-viaskin-peanut-patch-in-children-aged-4-7-years\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTI3NTMxOSM0MDI1MTk4NjQjMTAxMTE1Mg==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dbv-technologies-announces-submission-of-biologics-license-application-to-u-s-fda-for-the-viaskin-peanut-patch-in-children-aged-4-7-years\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dbv-technologies-announces-submission-of-biologics-license-application-to-u-s-fda-for-the-viaskin-peanut-patch-in-children-aged-4-7-years\\\/\",\"name\":\"DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the\u00a0VIASKIN\u00ae Peanut Patch in Children Aged 4-7 Years - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dbv-technologies-announces-submission-of-biologics-license-application-to-u-s-fda-for-the-viaskin-peanut-patch-in-children-aged-4-7-years\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dbv-technologies-announces-submission-of-biologics-license-application-to-u-s-fda-for-the-viaskin-peanut-patch-in-children-aged-4-7-years\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTI3NTMxOSM0MDI1MTk4NjQjMTAxMTE1Mg==\",\"datePublished\":\"2026-09-29T22:31:59+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dbv-technologies-announces-submission-of-biologics-license-application-to-u-s-fda-for-the-viaskin-peanut-patch-in-children-aged-4-7-years\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dbv-technologies-announces-submission-of-biologics-license-application-to-u-s-fda-for-the-viaskin-peanut-patch-in-children-aged-4-7-years\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dbv-technologies-announces-submission-of-biologics-license-application-to-u-s-fda-for-the-viaskin-peanut-patch-in-children-aged-4-7-years\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTI3NTMxOSM0MDI1MTk4NjQjMTAxMTE1Mg==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTI3NTMxOSM0MDI1MTk4NjQjMTAxMTE1Mg==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dbv-technologies-announces-submission-of-biologics-license-application-to-u-s-fda-for-the-viaskin-peanut-patch-in-children-aged-4-7-years\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the\u00a0VIASKIN\u00ae Peanut Patch in Children Aged 4-7 Years\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the\u00a0VIASKIN\u00ae Peanut Patch in Children Aged 4-7 Years - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/dbv-technologies-announces-submission-of-biologics-license-application-to-u-s-fda-for-the-viaskin-peanut-patch-in-children-aged-4-7-years\/","og_locale":"en_US","og_type":"article","og_title":"DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the\u00a0VIASKIN\u00ae Peanut Patch in Children Aged 4-7 Years - Market Newsdesk","og_description":"Ch\u00e2tillon, France, September 29, 2026 DBV Technologies Announces Submission of Biologics License Ap p lication to U.S. FDA for the\u00a0VIASKIN \u00ae Peanut Patch in Children Aged 4-7 Years The\u00a0BLA\u00a0is supported\u00a0by\u00a0the\u00a0results from the successful Phase 3\u00a0VITESSE trial\u00a0\u2013 the largest\u00a0immunotherapy clinical trial to date for this population.\u00a0 DBV has requested Priority Review of the BLA. DBV Technologies (Euronext: DBV \u2013 ISIN: FR0010417345 \u2013 Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company, today announced that the Company has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the VIASKIN\u00ae Peanut Patch in children with peanut allergy aged 4 through 7 years. DBV has requested Priority Review of the BLA. The FDA previously granted Breakthrough Therapy Designation to &hellip; Continue reading \"DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the\u00a0VIASKIN\u00ae Peanut Patch in Children Aged 4-7 Years\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/dbv-technologies-announces-submission-of-biologics-license-application-to-u-s-fda-for-the-viaskin-peanut-patch-in-children-aged-4-7-years\/","og_site_name":"Market Newsdesk","article_published_time":"2026-09-29T22:31:59+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTI3NTMxOSM0MDI1MTk4NjQjMTAxMTE1Mg==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dbv-technologies-announces-submission-of-biologics-license-application-to-u-s-fda-for-the-viaskin-peanut-patch-in-children-aged-4-7-years\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dbv-technologies-announces-submission-of-biologics-license-application-to-u-s-fda-for-the-viaskin-peanut-patch-in-children-aged-4-7-years\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the\u00a0VIASKIN\u00ae Peanut Patch in Children Aged 4-7 Years","datePublished":"2026-09-29T22:31:59+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dbv-technologies-announces-submission-of-biologics-license-application-to-u-s-fda-for-the-viaskin-peanut-patch-in-children-aged-4-7-years\/"},"wordCount":1083,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dbv-technologies-announces-submission-of-biologics-license-application-to-u-s-fda-for-the-viaskin-peanut-patch-in-children-aged-4-7-years\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTI3NTMxOSM0MDI1MTk4NjQjMTAxMTE1Mg==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dbv-technologies-announces-submission-of-biologics-license-application-to-u-s-fda-for-the-viaskin-peanut-patch-in-children-aged-4-7-years\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/dbv-technologies-announces-submission-of-biologics-license-application-to-u-s-fda-for-the-viaskin-peanut-patch-in-children-aged-4-7-years\/","name":"DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the\u00a0VIASKIN\u00ae Peanut Patch in Children Aged 4-7 Years - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dbv-technologies-announces-submission-of-biologics-license-application-to-u-s-fda-for-the-viaskin-peanut-patch-in-children-aged-4-7-years\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dbv-technologies-announces-submission-of-biologics-license-application-to-u-s-fda-for-the-viaskin-peanut-patch-in-children-aged-4-7-years\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTI3NTMxOSM0MDI1MTk4NjQjMTAxMTE1Mg==","datePublished":"2026-09-29T22:31:59+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dbv-technologies-announces-submission-of-biologics-license-application-to-u-s-fda-for-the-viaskin-peanut-patch-in-children-aged-4-7-years\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/dbv-technologies-announces-submission-of-biologics-license-application-to-u-s-fda-for-the-viaskin-peanut-patch-in-children-aged-4-7-years\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dbv-technologies-announces-submission-of-biologics-license-application-to-u-s-fda-for-the-viaskin-peanut-patch-in-children-aged-4-7-years\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTI3NTMxOSM0MDI1MTk4NjQjMTAxMTE1Mg==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTI3NTMxOSM0MDI1MTk4NjQjMTAxMTE1Mg=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dbv-technologies-announces-submission-of-biologics-license-application-to-u-s-fda-for-the-viaskin-peanut-patch-in-children-aged-4-7-years\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the\u00a0VIASKIN\u00ae Peanut Patch in Children Aged 4-7 Years"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1006876","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1006876"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1006876\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1006876"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1006876"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1006876"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}